✨HTGF Deep Dive: Deep-Tech Matrix, Interview with Francesco Sciortino, CEO of Proxima Fusion
HTGF | High-Tech Gründerfonds
We believe in tech. We invest in people.
Dear readers, welcome to the July edition of the HTGF Deep Dive newsletter. Once again, we have compiled exciting news, fresh insights and practical inspiration from the HTGF ecosystem.
Deep-tech startups have the potential to transform entire industries in the long term, making them particularly exciting for investors. At the same time, many teams struggle to communicate their technological potential clearly and convincingly. Our deep-tech experts Dr Gernot Berger , Dr Olaf Joeressen and Yann Fiebig have taken on this challenge: in their new article, they introduce the HTGF Deep-Tech Matrix – a practical tool that helps start-ups structure their development and communicate it in a targeted manner.
We highlight a very specific deep-tech case in an interview with Francesco Sciortino , CEO and co-founder of Proxima Fusion . The HTGF portfolio company recently raised €130 million in a Series A round to advance the commercialisation of fusion energy. In the interview, Sciortino explains the potential of the Stellaris reactor and how the journey from research to start-up unfolded.
Further financing news from our portfolio: Certivity receives €13.3 million. Sdui secures strategic investment led by Bain Capital . Bosch Ventures invests in smart energy pioneer Rabot Energy , and FlyNex completes another round of financing. Carelane receives €2.6 million in seed financing.
We welcome Stackgini (formerly Softwaregini) to the HTGF family in July, which is emerging from stealth mode with pre-seed financing and its first DAX40 customer. Also: EvlaBio is launching with €21 million in seed funding to develop a monoclonal antibody for patients with chronic kidney disease.
Enjoy reading!
The HTGF Team
HTGF Deep-Tech Matrix: Navigating the growth path of technology-driven startups
Deep-tech companies develop technologies that can transform entire industries. That makes them exciting – especially for investors. Yet many startups struggle to clearly explain their potential. Often, what’s missing is a consistent and compelling story. HTGF experts Dr. Gernot Berger , Dr. Olaf Joeressen , and Yann Fiebig have tackled this challenge. In a recent paper, they outline what really matters for deep-tech startups – and present a practical tool to help: the HTGF Deep-Tech Matrix.
Making commercial fusion a reality: An Interview with Proxima Fusion’s Francesco Sciortino
Proxima Fusion recently raised a €130 million Series A. We sat down with CEO and Co-founder Francesco Sciortino to discuss the promise of their Stellaris reactor, their journey from research to startup, the potential impact of their “Alpha” demonstration system, and his advice for other deep-tech founders facing major challenges.
10th Life Science Pitch Day at the IZB: Where Visionaries Meet Investors
During the anniversary Pitch Day at the IZB - Innovation and Start-up Center Biotechnology , ten selected startups presented their groundbreaking ideas to a high-caliber panel of investors.
Welcome to the HTGF Family
Stackgini (formerly Softwaregini) emerges from stealth mode – with Pre-Seed-Financing, DAX 40 clients and the goal of revolutionizing IT decision-making.
EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease.
More News from the HTGF Family
Upcoming Events
Chemistry Pitch Day
Organized by HTGF | High-Tech Gründerfonds and WACKER , this year's Chemistry Pitch Day will take place 28 October in Munich. Take your opportunity and present your technology to an exclusive audience of investors, corporate VCs, and industry experts!
Pitch Feedback Session: From Campus to Company
Great ideas are often born on campus. But the path from idea to successful startup requires more than just a vision – it needs a convincing pitch.
Calling All Innovators in Protein and RNA Therapeutics
Are you a start-up or early-stage developer with pioneering advances in protein or RNA therapeutics? Present your breakthrough solutions at the upcoming Symposium at the state-of-the-art WACKER Biotechnology Center in Munich on September 18th and 19th.
HTGF
High-Tech Gründerfonds Management GmbH | www.htgf.de
All rights reserved. | Privacy Policy Telephone: +49 (0)228 82300-100 | info@htgf.de Investors Advisory Board: Dr. Armgard Wippler (Chairwoman) Managing Directors: Dr. Alexander von Frankenberg, Dr. Achim Plum, Romy Schnelle Commercial Register: Amtsgericht Bonn HRB 13863 Registered office of the company: Bonn
Founder Implisense
1wSpannende Methodik. Gerade für den #Wissenschaftstransfer wäre so eine Methodik - eingebunden in ein datengestütztes Live-System - vermutlich hilfreich, um auch über die Zeit eine aktuelle Einschätzung zu erhalten.